Clinical effects of teriparatide, abaloparatide, and romosozumab in postmenopausal osteoporosis

Ebina, Kosuke; Etani, Yuki; Noguchi, Takaaki et al.

Journal of Bone and Mineral Metabolism, 2024, 43(1), 3-9

Number of Access:1,009（2025-07-24 02:26 Counts）

Identifier to cite or link to this item: https://hdl.handle.net/11094/98098

Link to primary information 

File Format Terms of use Size Views Date.Available Description information
JBoneMinerMetab_s00774-024-01536-0 pdf None 624 KB 392 2024.09.19  
Creative Commons : Attribution

Item Information

Output File Export EndNote Basic Export Mendeley

Title
Clinical effects of teriparatide, abaloparatide, and romosozumab in postmenopausal osteoporosis
Creator
NRID
1000070612076 1000070612076
researchmap permalink
k-ebina k-ebina
Scopus Author ID
8415453300 8415453300
ORCID
0000-0002-2426-1024 0000-0002-2426-1024
CreatorName
Ebina, Kosuke
NRID
1000060898930 1000060898930
ORCID
0000-0001-5741-5969 0000-0001-5741-5969
researchmap permalink
Yetani0302 Yetani0302
CreatorName
Etani, Yuki
NRID
1000050812294 1000050812294
researchmap permalink
takaakinoguchi takaakinoguchi
ORCID
0000-0001-9938-6780 0000-0001-9938-6780
CreatorName
Noguchi, Takaaki
NRID
1000000283747 1000000283747
researchmap permalink
ken-nakata ken-nakata
Scopus Author ID
7402151308 7402151308
CreatorName
Nakata, Ken
NRID
1000030448435 1000030448435
ORCID
0000-0002-5107-8209 0000-0002-5107-8209
researchmap permalink
okadaseiji okadaseiji
Scopus Author ID
35079139100 35079139100
CreatorName
Okada, Seiji
Subject
Abaloparatide
Osteoanabolic agent
Postmenopausal osteoporosis
Romosozumab
Teriparatide
Description
The version of record of this article, first published in Journal of Bone and Mineral Metabolism, is available online at Publisher’s website: https://doi.org/10.1007/s00774-024-01536-0.
Abstract
In the management of osteoporosis, anti-resorptive agents serve as a primary therapeutic approach. However, in cases where individuals exhibit an increased susceptibility to fractures, such as those characterized by severe low bone mass or a history of vertebral or hip fractures that markedly diminish life expectancy, the immediate reduction of fracture risk through the administration of osteoanabolic agents could be beneficial. Teriparatide, available in daily, once-weekly, or twice-weekly dosages, along with abaloparatide and romosozumab, constitutes a trio of such agents. Each of these medications is defined by unique characteristics, distinct efficacy profiles, and specific adverse effects. There is growing evidence to suggest that these agents have a superior effect on enhancing bone mineral density and reducing fracture incidence when compared to traditional bisphosphonate therapies. Nonetheless, their employment demands thorough consideration of clinical indications, which includes evaluating economic factors, the frequency of injections required, and the potential for adverse effects. The objective of this review is to consolidate the current evidence focusing primarily on the efficacy of these agents, with the goal of enhancing understanding and aiding in making more informed treatment decisions, particularly for those individuals who are at an elevated risk of fractures.
Publisher
Springer
Source Title
Journal of Bone and Mineral Metabolism
Volume (Issue)
43(1)
Page
3-9
Date of Issued
2024-07-10
Language
English
Handle URL
https://hdl.handle.net/11094/98098
PISSN
09148779
eISSN
14355604
Relation.isIdenticalTo
DOI (Publisher Version)
https://doi.org/10.1007/s00774-024-01536-0
Access Rights
open access
CopyRight
This article is licensed under a Creative Commons Attribution 4.0 International License.
oaire:version
Version of Record
Category
学術雑誌論文 Journal Article